ProfileGDS5678 / 1421229_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 29% 30% 30% 29% 29% 29% 28% 30% 29% 29% 29% 30% 31% 29% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6840229
GSM967853U87-EV human glioblastoma xenograft - Control 22.6711930
GSM967854U87-EV human glioblastoma xenograft - Control 32.674330
GSM967855U87-EV human glioblastoma xenograft - Control 42.6197429
GSM967856U87-EV human glioblastoma xenograft - Control 52.6161929
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.7274829
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6878628
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6690130
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6379329
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6426229
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6575429
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6447530
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7096631
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6629629